Merck Sharp + Dohme Corp.

Caterpillar Inc.

Zhiyong Hu

Michael W Miller

Ping Liu

Duane E DeMong

Scott D Edmondson

Harold B Wood

Andrew William Stamford

Gregori J Morriello

Bowei Wang

Cheng Zhu

Helen Y Chen

Wanying Sun

Tao Yu

Liping Wang

Yuping Zhu

Zhiqiang Guo

John A McCauley

Barbara A Pio

Dong Xiao

Steven L Colletti

Feroze Ujjainwalla

Xing Dai

Songnian Lin

Yong Zhang

Ronald M Kim

John S Debenham

Milana M Maletic

Harry R Chobanian

Jing Su

Shuzhi Dong

Rajan Anand

Yan Guo

Richard Berger

Timothy A Blizzard

Jason W Szewczyk

Kake Zhao

Christopher W Plummer

Brian T Campbell

Jiayi Xu

William Bert Geiss

Lehua Chang

Joel M Harris

Kevin D Dykstra

Timothy Allen Blizzard

Vincent Colandrea

Libo Xu

Kallol Basu

Bart Harper

Nam Fung Kar

Yili Chen

Rui Zhang

Alan Whitehead

Joie Garfunkle

Ming Wang

Christopher R Moyes

Cangming Yang

Timothy Allen McKinley

Zack Zhiqiang Guo

Candido Gude

Yong Huang

Byron Dubois

Sunita V Dewnani

Chunrui Sun

Weixue Tian

Byron Gabriel Dubois

William Henry Baar, Iii

Megan Macala

Timothy A Mckinley

William H Baar Iii

John A Mccauley

Michael Miller

Vincent J Colandrea

Duane E Demong

William B Geiss

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of structural formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of structural formula I, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Chromane amidine monobactam compounds for the treatment of bacterial infections

The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, R, R, Rand n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Tricyclic heterocycle compounds useful as HIV integrase inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I). 

Antidiabetic bicyclic compounds

A track pin may comprise a body that includes a generally cylindrical configuration defining an axis of rotation, a circumferential direction and a radial direction, the body defining a first end, a second end and a peripheral surface extending from the first end to the second end. The peripheral surface may include a first lobed portion spaced axially away from the first end and the second end and including a series of convex arcuate segments and concave arcuate segments joined to each other tangentially, forming an undulating surface.

Lobed track pin

The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity. 

Isoquinoline derivatives as MGAT2 inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic compounds

Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. 

Substituted cyclopropyl compounds useful as GPR119 agonists

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included. 

Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment

Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment

Growing community of inventors

Livingston, NJ, United States of America

Zhiyong Hu